the history of angion
Angion was founded in 1998 by Dr. Itzhak Goldberg. From our incorporation through 2014, our efforts were primarily focused on researching a number of pathways related to serious organ diseases and applying our medicinal chemistry expertise towards creating potential therapeutics to address the unmet medical needs of patients.
Our lead program, ANG-3070, entered Phase 1 in late 2019 and we reported positive data from that trial in early 2021. ANG-3070 is now in a Phase 2 trial in patients with primary proteinuric disease and we intend to start a second Phase 2 trial of ANG-3070 in patients with idiopathic pulmonary fibrosis.